Metabiomed메타바이오메드
059210 · KOSDAQ · ₩059210 · 메타바이오메드
₩3,625▼ ₩10 (0.28%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 52.6% | 52.1% | 50.4% | 45.7% | 42.3% | 42.5% |
| Operating margin | 18.9% | 20.8% | 18.3% | 12.9% | 7.7% | 8.4% |
| Net margin | 16.8% | 10.7% | 23.8% | 12.1% | 3.8% | 16.2% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −1.7% | +9.5% | +13.2% | +20.5% | +17.3% | — |
| Operating income growth | −10.7% | +24.4% | +60.2% | +101.4% | +8.0% | — |
| Net income growth | +54.6% | −51.0% | +122.2% | +283.6% | −72.4% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 13.4% | 10.1% | 27.4% | 15.4% | 4.4% | 16.3% |
| Return on assets | 9.4% | 5.9% | 14.5% | 7.8% | 3.2% | 9.4% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 49.3% | 49.4% | 84.5% | 79.1% | 90.8% | 71.6% |
| Net debt to equity | 23.1% | 19.3% | −9.3% | 45.6% | 48.2% | 40.1% |
| Current ratio | 153.1% | 138.9% | 127.7% | 112.3% | 113.7% | 126.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Metabiomed / 메타바이오메드 / 059210 / KRX:059210
Source: KRX statistical information